On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
ORGANIZATION
Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
Japan’s two major pharma lobbies are retaining their chiefs for one more year to weather upcoming discussions to delineate the scope of so-called “off-year” re-pricing, which will begin in April 2021, people familiar with the matter told Jiho. Shionogi President…
To read the full story
Related Article
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
ORGANIZATION
- JMA’s New Pharma Affairs Exec Wants More Stringent Rules on Sakigake, Conditional Approval
August 11, 2020
- Bayer Yakuhin President Heike Prinz Elected New EFPIA Japan Chief
August 3, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- Pharmacist Group Says Drug Price Survey This Year “Utterly Unacceptable”
July 21, 2020
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…